schizophrenia

Does cannabis affect cognitive functioning in patients with schizophrenia?

Authors: Hajar Rachid, Zineb Saif, Salma Raoui, Zineb Serhier, Mohamed Agoub

Journal: Schizophrenia Research: Cognition

Year Published: 2024

Introduction: Cannabis use impairs cognitive performance in healthy subjects; several studies have shown improved cognitive outcomes in schizophrenic patients using cannabis. The aim of this study was to evaluate the effects of cannabis use on cognitive […]

Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

Authors: Colin Sauder, Luke A Allen, Elizabeth Baker, Andrew C Miller, Steven M Paul, Stephen K Brannan

Journal: Translational Psychiatry

Year Published: 2022

The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in Alzheimer’s disease and schizophrenia. We present data on the effect of KarXT (xanomeline-trospium) on cognition in schizophrenia from the 5-week, randomised, double-blind, placebo-controlled EMERGENT-1 […]

The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial

Authors: Wolfgang Marx, David R Skvarc, Mohammadreza Mohebbi, Adam J Walker, Alcy Meehan, Alyna Turner, Andrea Baker, Seetal Dodd, Sue M Cotton, James Graham Scott, Bianca E Kavanagh, Melanie M Ashton, Ellie Brown, John J McGrath, Michael Berk, Olivia May Dean

Journal: Frontiers in Psychiatry

Year Published: 2021

Background Cognitive impairment is prevalent and often highly burdensome in people with schizophrenia. The aim of this study was to investigate if mangosteen (Garcinia mangostana Linn.) pericarp extract may be an effective intervention to improve cognitive […]

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D 1 receptor positive allosteric modulator in patients with schizophrenia

Authors: Amit Desai, Lauren Benner, Ruishan Wu, Lev Gertsik, Paul Maruff, Gregory A Light, Tolga Uz, Gerard J Marek, Tong Zhu

Journal: Neuropsychopharmacology

Year Published: 2020

ASP4345, a novel dopamine D1 receptor positive allosteric modulator, is being evaluated for the treatment of cognitive impairment associated with schizophrenia (CIAS). This phase 1 multiple ascending-dose study (NCT02720263) assessed the safety, tolerability, and pharmacodynamics of […]

Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia

Authors: Brian J Miller, Andrei Pikalov, Cynthia O Siu, Michael Tocco, Joyce Tsai, Philip D Harvey, John W Newcomer, Antony Loebel

Journal: Comprehensive Psychiatry

Year Published: 2020

Background: Accumulating evidence has implicated insulin resistance and inflammation in the pathophysiology of cognitive impairments associated with neuropsychiatric disorders. This post-hoc analysis based on a placebo-controlled trial investigated the effect of inflammation (indexed by CRP) and […]

1 2 3 6

Back to Publications